ONE SIZE FITS NONE Personalized protocols, tuned to your body
Clinical trial results discussed in this article - STEP 1 (14.9% average body weight loss with semaglutide), SURMOUNT-1 (20.9% average body weight loss with tirzepatide), and SELECT (20% reduced risk of major cardiovascular events with FDA-approved Wegovy in a specific patient population) - relate to studied active ingredients and specific FDA-approved formulations in controlled trial populations and should not be interpreted as guaranteed outcomes for any individual patient or compounded formulation
Elevate Health Group is a leading primary care and internal medicine practice serving the communities of Glendale, Burbank, and La Canada, California since 2015
Complementing GLP-1 medications like semaglutide or tirzepatide
While it might not be the quickest option, consulting with your trusted physician is a great way to make sure youre making an informed and safe decision for your body
Preclinical studies in rodents have also shown a relationship between GLP-1 RAs and the development of thyroid c-cell tumors, including medullary thyroid carcinoma (MTC)